{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-008159","form_type":"8-K","ticker":"CNSP","cik":"0001729427","company_name":"CNS Pharmaceuticals, Inc.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.210991+00:00","generated_at":"2026-06-08T02:35:54.691216+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CNS Pharma Q3 net loss $4.5M; Berubicin enrollment at 239, interim data Dec 2023","bullets":["Net loss of $4.5M vs $3.4M in Q3 2022; R&D expenses rose to $3.4M on clinical progress.","Cash at Sept 30 was $0.9M; raised $2.6M in October via warrant/ATM; expects to fund operations through Q4 2023.","Enrollment in potentially pivotal Berubicin GBM study reached 239 patients; full enrollment expected Dec 2023.","Topline data from interim analysis expected in December 2023; 45 of 60 trial sites activated across US and Europe."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-008159","json":"https://secwatch.observer/filing/0001683168-23-008159.json","markdown":"https://secwatch.observer/filing/0001683168-23-008159.md","text":"https://secwatch.observer/filing/0001683168-23-008159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823008159/0001683168-23-008159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823008159/cns_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:35:54.691216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5010876e70242b2f5095887a1694ae5fa8d047c5","claim":"CNS Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 15, 2023, CNS Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the period ended September 30, 2023 and recent operational highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823008159/0001683168-23-008159-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}